IL-2 Engineering & Application Development Services
Creative Biolabs' IL-2 engineering & application development services are a comprehensive platform designed to solve the selectivity and toxicity limitations of cytokine therapeutics. We offer end-to-end development of next-generation IL-2 analogs, including receptor-selective muteins, long-acting PEGylated variants, and targeted immunocytokines (fusion proteins). Our process, anchored in QbD principles and rigorous functional validation, ensures that clients receive high-purity, custom-designed biotherapeutics with confirmed cell-type specificity and optimized pharmacokinetics. By partnering with us, you gain a validated, optimized lead candidate, enabling you to accelerate advanced preclinical studies and achieve superior therapeutic outcomes in oncology or autoimmune research with reduced systemic toxicity.
Introduction What We Can Offer Types of Our Services Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Introduction of IL-2 Engineering
IL-2 is a central cytokine governing T cell growth, crucial for both promoting T cell immunity (against cancer) and enforcing immune tolerance. The major hurdle is its indiscriminate activity via the IL-2Rαβγ receptor, leading to severe toxicity and therapeutic conflicts. IL-2 engineering & application development services focus on structurally modifying the IL-2 molecule to achieve cell-type selective signaling. This precision allows for the safe delivery of the therapeutic signal only to the desired T-cell subset, representing a major paradigm shift in modern immunotherapy development.
Discover how we can help, request a consultation.
Fig.1 Engineering IL-2 for synergistic combination with immune checkpoint blockade in cancer. 1
What We Can Offer
Customized Affinity & Receptor Engineering
We provide rational, structure-guided design to create tailor-made IL-2 muteins. This ensures precise control over binding affinity to the IL-2R components (α, β, γ), allowing us to fine-tune the signal for exclusive Treg expansion (for autoimmunity) or highly selective Teff/NK activation (for oncology).
Seamless One-Stop Development
Creative Biolabs integrates the entire process from initial in silico target design and codon usage optimization through to high-titer recombinant protein expression and comprehensive functional validation. This single-source approach significantly reduces technical transfer risks and shortens your development timeline.
Advanced Immunocytokine Architecture
Our expertise includes state-of-the-art target-specific delivery via fusion proteins. We seamlessly conjugate engineered IL-2 variants (IL-2v) to targeting moieties (antibodies/scFv) against antigens like PD-1 or FAP, ensuring the potent therapeutic signal is localized directly to the disease site within the tumor microenvironment (TME).
IL-2 Engineering & Application Development Services at Creative Biolabs
This service focuses on extending the half-life of IL-2 variants to enable less frequent dosing and maintain therapeutic concentrations. We utilize advanced techniques such as site-specific PEGylation and fusion to Fc domains or serum albumin, ensuring minimal interference with receptor binding while maximizing in vivo exposure.
We design custom IL-2 mutants using rational design and structure-guided mutagenesis. This service is subdivided by target function. Mutations are introduced to eliminate binding to IL-2Rα, thus selectively promoting anti-tumor activity. Variants are designed with reduced affinity.
This advanced service involves creating immunocytokines by fusing the IL-2 variant to a targeting moiety. Fusing CD25-silent IL-2 variants to anti-PD-1 antibodies for delivery to highly exhausted, PD-1-expressing CD8+ T-cells within the TME. Fusing IL-2 to antibodies that recognize tumor-specific or TME-specific antigens (e.g., FAP) to ensure localized activation and reduce systemic effects.
We provide the necessary IL-2 variants and functional data packages to support combination strategies, particularly with immune checkpoint inhibitors. This includes validating the synergistic effect where the IL-2 signal works in concert with PD-1 blockade to reverse T cell exhaustion.
Why Choose Us?
|
Key Advantages
|
Unique Features
|
|
Precision Signaling Control
|
We move beyond simple CD25 ablation to design mutagens that either completely avoid IL-2Rα for Teff selectivity or, conversely, create IL-2Rα-biased agonists for Treg expansion, based on your specific research goal.
|
|
Targeted Immunocytokine Development
|
Our platform specializes in fusing IL-2 variants (IL-2v) to antibodies against key tumor markers like PD-1 or FAP. This spatial targeting approach ensures the potent IL-2 signal is delivered directly to exhausted, PD-1-expressing CD8+ T-cells in the TME, maximizing efficacy while maintaining systemic safety.
|
|
Advanced Exhaustion Biology Insight
|
We leverage recent published data showing that IL-2 signaling via STAT5 can override the Tox-driven exhaustion program in CD8+ T-cells. Our designs aim to restore this functional capacity in exhausted cells for enhanced therapeutic output.
|
To initiate engagement with Creative Biolabs' platform, please formally request a detailed service proposal.
Customer Reviews
-
Superior TME Targeting
The utilization of Creative Biolabs' services has significantly expedited the design and rigorous validation of our innovative IL-2 immunocytokine. Specifically, the PD-1-targeted variant demonstrated superior STAT5 signaling activity within PD-1-high tumor-infiltrating lymphocytes in comparison to its unconjugated IL-2v counterpart. - Dr. L**a M.
-
Improved PK Profile
Using Creative Biolabs' services has significantly improved our drug candidate's half-life and in vivo stability through optimized, site-specific PEGylation strategies. This approach gave us a crucial advantage over non-specifically PEGylated alternatives, leading to more favorable dosing schedules. -Dr. A****w K.
FAQs
Q: How do you guarantee the selectivity of your IL-2 variants, given the complexity of the receptor chains?
A: We use a multi-step validation process. After designing the mutein based on the IL-2R crystal structure, we use SPR/BLI technology to precisely quantify binding affinities to isolated IL-2Rα, β, and γ chains. Crucially, we then validate this in vitro using STAT5 phosphorylation assays on primary Treg (high CD25) versus Teff (CD8+) cells.
Q: What are the main risks associated with IL-2 engineering, and how does Creative Biolabs mitigate them?
A: The main risks are loss of desired selectivity, manufacturing issues, and systemic toxicity. We mitigate these risks through rational, structure-guided design, rigorous QC during purification, and, for systemic toxicity, by focusing on our Target-Specific Delivery services (e.g., PD-1 fusion), which localize the powerful IL-2 signal.
Related Services
Cytokine Production Measurement Service
This service provides quantitative and qualitative measurement of cytokine expression, secretion, and signaling activity (e.g., STAT phosphorylation) across various biological matrices.
Learn More →
Antibody Engineering
Utilize our high-throughput antibody discovery and optimization platform to generate the targeting moieties needed for your IL-2 immunocytokines.
Learn More →
How to Contact Us
Creative Biolabs provides end-to-end support for developing next-generation IL-2 therapeutics, from structural design and mutagenesis to in vitro functional validation and PK assessment. Our focus is on precision, selectivity, and safety to accelerate your drug candidate into development. Contact our team for more information and to discuss your project.
Reference
-
Im, Se Jin et al. "Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends." Experimental & molecular medicine vol. 56,9 (2024): 1900-1908. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s12276-024-01301-3
For Research Use Only | Not For Clinical Use
